In this group, SBP decreased from 148.7 ± 13.4
to 136.2 ± 13.1 mmHg (p = 0.001) but DBP did not change (from 84.2 ± 10.8 to 79.9 ± 6.47 mmHg, p = 0.08). The potency increased from selleck chemical 1.67 ± 0.58 to 2.00 ± 0.53 (p = 0.018) and the number of antihypertensive tablet decreased from 2.10 ± 0.71 to 1.38 ± 0.59 (p < 0.001) as well as the number of total tablets (from 3.89 ± 2.81 to 2.94 ± 2.25, p < 0.001) but the costs of antihypertensive drugs did not change (from 4,876 ± 2,200 to 4,672 ± 971 yen, p = 0.68). Comparison of baseline characteristics between non-CKD and CKD patients We compared the baseline characteristics https://www.selleckchem.com/products/gsk2879552-2hcl.html between non-CKD and CKD patients. CKD showed lower eGFR (75.3 ± 17.4 vs. 44.1 ± 22.8 mL/min/1.73 m2, p < 0.001), CKD patients showed slightly higher SBP (139.0 ± 15.1 vs. 146.9 ± 22.5 mmHg, p = 0.054) with the similar DBP (83.7 ± 10.3 vs. 81.3 ± 15.4 mmHg, p = 0.39) (Fig. 3a, b), even though antihypertensive drug potency was greater (2.06 ± 0.85 vs. 2.60 ± 1.24, p = 0.02) (Fig. 3c) and the number of antihypertensive tablets taken were higher in CKD patients (2.33 ± 0.92
vs. 2.98 ± 1.49 tablets, p = 0.015). The costs for the antihypertensive drugs were significantly higher in CKD patients than non-CKD patients (6,276 yen ± 2,920 yen in non-CKD patients vs. 7,556 yen ± 3,024 yen in CKD, p = 0.047) (Fig. 3d). Fig. 3 Comparison between non-CKD and CKD patients. a, b Changes in blood pressure in non-CKD and CKD patients. In non-CKD patients, SBP significantly decreased from 139.0 ± 15.1 to 134.3 ± 13.0 mmHg (p = 0.027) and DBP significantly decreased from 84.0 ± 10.3 to 80.3 ± 7.8 mmHg (p = 0.012). In CKD patients, SBP significantly decreased from 146.9 ± 22.5 to 135.2 ± 22.1 mmHg (p = 0.0015) and DBP significantly decreased
from 81.3 ± 15.4 to 76.3 ± 14.5 mmHg (p = 0.019). c Changes in antihypertensive potency in non-CKD and CKD patients. The antihypertensive potency was higher in CKD patients than non-CKD patients (2.06 ± 0.85 in non-CKD vs. 2.60 ± 1.24 in CKD, p = 0.020). The potency did not differ significantly before and after the changes (from 2.06 ± 0.85 to 2.08 ± 0.60, p = 0.86 in non-CKD and from 2.60 ± 1.24 to 2.50 ± 0.85, p = 0.46 in CKD). d Monthly cost for antihypertensive drugs in non-CKD Phospholipase D1 and CKD patients. 6,276 ± 2,920 yen in non-CKD patients, p = 0.047) and were significantly decreased in both groups (p = 0.047) Influence of the selleck chemicals llc switch in non-CKD and CKD patients In non-CKD patients, both SBP (from 139.0 ± 15.1 to 134.3 ± 13.0 mmHg) (p = 0.027) and DBP (from 84.0 ± 10.3 to 80.3 ± 7.8 mmHg) (p = 0.012) significantly decreased after the switch (Fig. 3a).